BioSpace News Archive

Inotrem, an advanced clinical stage biotech company specialized in immunotherapies for acute and chronic inflammatory syndromes, announced that it has filed a patent to protect a new therapeutic modality against TREM-1, a monoclonal antibody.

Tiziana Life Sciences plc announces that it has signed an agreement with FHI Clinical, a global clinical contract research organization, to conduct a Phase 2 Proof-of-concept study in Brazil to evaluate the safety, tolerability and efficacy of intranasal Foralumab in hospitalized patients with severe coronavirus disease 2019 and pulmonary inflammation.

Enanta Pharmaceuticals, Inc., a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, reported new preclinical data for EDP-721, a novel, oral hepatitis B virus RNA destabilizer being developed for use in an all-oral combination regimen for HBV.

Sosei Group Corporation announces that the first healthy subject has been dosed with HTL0022562 in a Phase 1 clinical study.

Alzheon, Inc., a clinical-stage biopharmaceutical company developing a broad portfolio of product candidates and diagnostic assays for patients suffering from Alzheimer’s disease and other neurodegenerative disorders, announced that it has achieved enrollment target of 80 patients for its Phase 2 biomarker study of ALZ-801 in Early AD patients, who carry either one or two copies of the ε4 allele of apolipoprotein E gene.

Praxis Bioresearch, a biopharmaceutical company focused on the discovery and development of novel therapeutics for chronic central nervous system disorders, announced that it has successfully completed a microdose study in healthy volunteers under an exploratory IND approved by FDA in January 2021.

Dante Labs, a leading genomics and diagnostics company, announced the acquisition of Cambridge Cancer Genomics, a groundbreaking Y-Combinator company & leader in machine learning for clinical oncology, to create a single platform with unparalleled capabilities in genomics and oncology data analysis.

SQZ Biotechnologies Company, focused on unlocking the full potential of cell therapies for multiple therapeutic areas, presented preclinical regenerative medicine data showing that the company’s Cell Squeeze® technology can be used to generate neurons from induced human pluripotent stem cells through the single delivery of an mRNA encoding fate-specifying transcription factor.

Pfizer Inc. announced that the first participant has been dosed in TALAPRO-3, a global, randomized, double-blind, placebo-controlled Phase 3 clinical trial.

BD, a leading global medical technology company, announced it has received 510 clearance from the U.S. Food and Drug Administration for the PeritX™ Peritoneal Catheter System for the drainage of symptomatic, recurrent non-malignant ascites.